Gray zone lymphoma

Gray zone lymphoma (GZL) is a rare type of lymphoma that shares features with two different types of lymphoma: Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). It is also known as lymphoma between Hodgkin lymphoma and diffuse large B-cell lymphoma.

Overview[edit]

GZL is a rare and aggressive type of lymphoma. It was first described in 2005 and is recognized as a distinct entity by the World Health Organization (WHO). GZL can occur at any age, but it is most common in young adults. The cause of GZL is unknown.

Symptoms[edit]

The symptoms of GZL are similar to those of other types of lymphoma. They may include fever, night sweats, weight loss, and swollen lymph nodes. Some people with GZL may also have anemia or other blood disorders.

Diagnosis[edit]

The diagnosis of GZL is based on the results of a biopsy of an affected lymph node. The biopsy sample is examined under a microscope to look for the characteristic features of GZL. Additional tests, such as imaging studies and blood tests, may also be performed to determine the extent of the disease.

Treatment[edit]

The treatment of GZL is challenging because it does not respond well to the standard treatments for either HL or DLBCL. Treatment options may include chemotherapy, radiation therapy, stem cell transplantation, and immunotherapy. The choice of treatment depends on the individual patient's condition and the extent of the disease.

Prognosis[edit]

The prognosis for people with GZL is generally poor, with a median survival time of less than 2 years. However, some people with GZL have a more favorable prognosis, especially if the disease is diagnosed early and treated aggressively.